Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman van Vlijmen

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Clinical and Translational Science|April 16, 2025
A Patient-Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing CandidatesAlina Meyer, Bola Khalil, Margarita Iljin, et al.
Journal of Medicinal Chemistry|June 28, 2002
Identification of potent and novel alpha4beta1 antagonists using in silico screeningJuswinder Singh, Herman Van Vlijmen, Yusheng Liao, et al.
Journal of Chemical Theory and Computation|October 30, 2023
Alchemical Free Energy Calculations on Membrane-Associated ProteinsMichail Papadourakis, Hryhory Sinenka, Pierre Matricon, et al.
Journal of Computer-Aided Molecular Design|October 5, 2002
3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonistsJuswinder Singh, Herman van Vlijmen, Wen-Chemg Lee, et al.
The Journal of Biological Chemistry|December 6, 2002
Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)Pascal Schneider, Dian Olson, Aubry Tardivel, et al.
Journal of Computer-Aided Molecular Design|December 26, 2016
Collaborating to improve the use of free-energy and other quantitative methods in drug discoveryBradley Sherborne, Veerabahu Shanmugasundaram, Alan C Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2009
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion proteinDirk Roymans, Hendrik L De Bondt, Eric Arnoult, et al.
Journal of Medicinal Chemistry|November 30, 2004
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonistsHairuo Peng, Gnanasambandam Kumaravel, Gang Yao, et al.
Drug Discovery Today|January 20, 2024
The European Lead Factory: Results from a decade of collaborative, public-private, drug discovery programsHerman van Vlijmen, Andrew D Pannifer, Phil Cochrane, et al.
Protein Engineering, Design & Selection : PEDS|May 10, 2006
Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibodyCarl Reid, Mia Rushe, Matthew Jarpe, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Clinical and Translational Science|April 16, 2025
A Patient-Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing CandidatesAlina Meyer, Bola Khalil, Margarita Iljin, et al.
Journal of Medicinal Chemistry|June 28, 2002
Identification of potent and novel alpha4beta1 antagonists using in silico screeningJuswinder Singh, Herman Van Vlijmen, Yusheng Liao, et al.
Journal of Chemical Theory and Computation|October 30, 2023
Alchemical Free Energy Calculations on Membrane-Associated ProteinsMichail Papadourakis, Hryhory Sinenka, Pierre Matricon, et al.
Journal of Computer-Aided Molecular Design|October 5, 2002
3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonistsJuswinder Singh, Herman van Vlijmen, Wen-Chemg Lee, et al.
The Journal of Biological Chemistry|December 6, 2002
Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)Pascal Schneider, Dian Olson, Aubry Tardivel, et al.
Journal of Computer-Aided Molecular Design|December 26, 2016
Collaborating to improve the use of free-energy and other quantitative methods in drug discoveryBradley Sherborne, Veerabahu Shanmugasundaram, Alan C Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2009
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion proteinDirk Roymans, Hendrik L De Bondt, Eric Arnoult, et al.
Journal of Medicinal Chemistry|November 30, 2004
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonistsHairuo Peng, Gnanasambandam Kumaravel, Gang Yao, et al.
Drug Discovery Today|January 20, 2024
The European Lead Factory: Results from a decade of collaborative, public-private, drug discovery programsHerman van Vlijmen, Andrew D Pannifer, Phil Cochrane, et al.
Protein Engineering, Design & Selection : PEDS|May 10, 2006
Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibodyCarl Reid, Mia Rushe, Matthew Jarpe, et al.
Pageof 5